Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases
- 1 October 1999
- Vol. 86 (7), 1174-1181
- https://doi.org/10.1002/(sici)1097-0142(19991001)86:7<1174::aid-cncr11>3.0.co;2-8
Abstract
BACKGROUND To the authors' knowledge the prognosis of patients with intrapulmonary metastases (PM) of nonsmall cell lung carcinoma (NSCLC) has not yet been clarified fully and little is known regarding the characteristic changes that occur during the metastatic process, nor of their clinical significance. METHODS Formalin fixed and paraffin embedded material of primary and metastatic lesions resected from 34 patients with PM of NSCLC were stained immunohistochemically with proliferating cell nuclear antigen (PCNA) and CD44 and its variant isoforms. RESULTS Patients with NSCLC expressing PCNA in the primary tumor site (79.4%) showed a significantly poorer survival (5‐year survival rate of 20.2%) compared with the 5‐year survival rate of 57.1% for patients not expressing PCNA in the primary tumor site (P = 0.048). Patients expressing PCNA in the metastatic site (88.2%) also showed a significantly poorer prognosis than those not expressing PCNA (P = 0.036). Patients with squamous cell carcinoma expressed CD44 variant exon 6 (CD44v6) at a significantly higher rate than adenocarcinoma patients (P = 0.0164), but expression of CD44v6 was not a significant prognostic factor. Concordance of PCNA and CD44v6 expression between the primary and corresponding metastatic sites was observed in 65% of patients (22 of 34 patients) but no difference in prognosis was observed in relation to this concordance. Cox multivariate analyses indicated that expression of PCNA was a significant prognostic indicator for both primary and metastatic sites (P = 0.014 and P = 0.0095, respectively). CONCLUSIONS This study demonstrated that PCNA expression was a significant prognostic factor for both primary and metastatic lesions in PM patients. CD44v6 showed histogenesis of the tumor, but no relation with the prognosis could be ascertained. Cancer 1999;86:1174–81. © 1999 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Prognosis of ipsilateral intrapulmonary metastases in resected nonsmall cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 1997
- Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridizationGenes, Chromosomes and Cancer, 1997
- Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysisCancer, 1994
- Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.Proceedings of the National Academy of Sciences, 1992
- The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancerCancer, 1992
- Comparison of flow cytometric dna content in primary gastric carcinoma and metastasesJournal of Surgical Oncology, 1992
- A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cellsCell, 1991
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990
- Cyclin/PCNA is the auxiliary protein of DNA polymerase-δNature, 1987
- Multiple primary lung cancersThe Journal of Thoracic and Cardiovascular Surgery, 1975